Perimeter Systems, Inc.
Boston, United States· Est.
Developing precision gene therapy delivery platforms for oncology with enhanced tumor targeting and reduced off-target effects.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $45M
AI Company Overview
Developing precision gene therapy delivery platforms for oncology with enhanced tumor targeting and reduced off-target effects.
Oncology
Technology Platform
Novel gene therapy delivery platform with enhanced tumor-targeting capabilities using engineered vectors and tissue-specific targeting mechanisms.
Funding History
1GrowthUndisclosed
Opportunities
Potential to address the significant delivery challenges in oncology gene therapy, creating opportunities for partnerships with larger pharmaceutical companies and expansion into multiple cancer indications.
Risk Factors
Early-stage platform validation risk, competitive landscape with established gene therapy companies, and challenges in manufacturing novel delivery systems at commercial scale.
Competitive Landscape
Competes with oncology-focused gene therapy companies like Tessa Therapeutics and Adaptimmune, with differentiation centered on proprietary delivery technology rather than specific genetic payloads.